322 related articles for article (PubMed ID: 30690293)
21. Histopathological tumor response following neoadjuvant hyperthermic isolated limb perfusion in extremity soft tissue sarcomas: Evaluation of the EORTC-STBSG response score.
Stevenson MG; Hoekstra HJ; Song W; Suurmeijer AJH; Been LB
Eur J Surg Oncol; 2018 Sep; 44(9):1406-1411. PubMed ID: 29858098
[TBL] [Abstract][Full Text] [Related]
22. Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials.
Le Cesne A; Ouali M; Leahy MG; Santoro A; Hoekstra HJ; Hohenberger P; Van Coevorden F; Rutkowski P; Van Hoesel R; Verweij J; Bonvalot S; Steward WP; Gronchi A; Hogendoorn PCW; Litiere S; Marreaud S; Blay JY; Van Der Graaf WTA
Ann Oncol; 2014 Dec; 25(12):2425-2432. PubMed ID: 25294887
[TBL] [Abstract][Full Text] [Related]
23. The Prognostic Value of Lymphovascular Invasion in Truncal and Extremity Soft Tissue Sarcomas: An Analysis from the National Cancer Database.
Ethun CG; Lopez-Aguiar AG; Switchenko JM; Gillespie TW; Delman KA; Staley CA; Maithel SK; Cardona K
Ann Surg Oncol; 2019 Dec; 26(13):4723-4729. PubMed ID: 31502023
[TBL] [Abstract][Full Text] [Related]
24. Patterns of local recurrence and dose fractionation of adjuvant radiation therapy in 462 patients with soft tissue sarcoma of extremity and trunk wall.
Jebsen NL; Engellau J; Engström K; Bauer HC; Monge OR; Muren LP; Eide GE; Trovik CS; Bruland OS
Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):949-55. PubMed ID: 23725998
[TBL] [Abstract][Full Text] [Related]
25. First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials.
Young RJ; Natukunda A; Litière S; Woll PJ; Wardelmann E; van der Graaf WT
Eur J Cancer; 2014 Dec; 50(18):3178-86. PubMed ID: 25459395
[TBL] [Abstract][Full Text] [Related]
26. Complete pathological response to neoadjuvant treatment is associated with better survival outcomes in patients with soft tissue sarcoma: Results of a retrospective multicenter study.
Bonvalot S; Wunder J; Gronchi A; Broto JM; Turcotte R; Rastrelli M; Papai Z; Radaelli S; Lindner LH; Shumelinsky F; Cubillo A; Rutkowski P; Demaire C; Strens D; Nalbantov G
Eur J Surg Oncol; 2021 Aug; 47(8):2166-2172. PubMed ID: 33676792
[TBL] [Abstract][Full Text] [Related]
27. What is the standard indication of adjuvant or neoadjuvant chemotherapy in localized soft-tissue sarcoma?
Hindi N; Martin-Broto J
Curr Opin Oncol; 2021 Jul; 33(4):329-335. PubMed ID: 33973551
[TBL] [Abstract][Full Text] [Related]
28. [Responses of 109 adult soft tissue sarcoma patients to chemotherapy].
Qiu MZ; Xu F; Wang SS; Luo HY; Wang F; Li FH; Sun XF; Xu GC; Lin TY; Huang HQ; Jiang WQ; Guan ZZ; Xu RH
Ai Zheng; 2007 Dec; 26(12):1344-9. PubMed ID: 18076798
[TBL] [Abstract][Full Text] [Related]
29. Response to neoadjuvant chemotherapy combined with regional hyperthermia predicts long-term survival for adult patients with retroperitoneal and visceral high-risk soft tissue sarcomas.
Wendtner CM; Abdel-Rahman S; Krych M; Baumert J; Lindner LH; Baur A; Hiddemann W; Issels RD
J Clin Oncol; 2002 Jul; 20(14):3156-64. PubMed ID: 12118030
[TBL] [Abstract][Full Text] [Related]
30. Prognostic factors in adolescents and young adults (AYA) with high risk soft tissue sarcoma (STS) treated by adjuvant chemotherapy: a study based on pooled European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62771 and 62931.
Kasper B; Ouali M; van Glabbeke M; Blay JY; Bramwell VH; Woll PJ; Hohenberger P; Schöffski P
Eur J Cancer; 2013 Jan; 49(2):449-56. PubMed ID: 22975215
[TBL] [Abstract][Full Text] [Related]
31. Comparison of outcome and toxicity of postoperative intensity-modulated radiation therapy with two-dimensional radiotherapy in patients with soft tissue sarcoma of extremities and trunk.
Wang J; Song Y; Liu X; Jin J; Wang W; Yu Z; Liu Y; Li N; Fang H; Ren H; Tang Y; Tang Y; Chen B; Lu N; Qi S; Wang S; Li Y
Cancer Med; 2019 Mar; 8(3):902-909. PubMed ID: 30740916
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant chemotherapy and postoperative radiotherapy in high-risk soft tissue sarcoma patients defined by biological risk factors-A Scandinavian Sarcoma Group study (SSG XX).
Sundby Hall K; Bruland ØS; Bjerkehagen B; Zaikova O; Engellau J; Hagberg O; Hansson L; Hagberg H; Ahlström M; Knobel H; Papworth K; Zemmler M; Goplen D; Bauer HCF; Eriksson M
Eur J Cancer; 2018 Aug; 99():78-85. PubMed ID: 29929092
[TBL] [Abstract][Full Text] [Related]
33. Five-year results from a Scandinavian sarcoma group study (SSG XIII) of adjuvant chemotherapy combined with accelerated radiotherapy in high-risk soft tissue sarcoma of extremities and trunk wall.
Jebsen NL; Bruland ØS; Eriksson M; Engellau J; Turesson I; Folin A; Trovik CS; Hall KS
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1359-66. PubMed ID: 20933339
[TBL] [Abstract][Full Text] [Related]
34. The risk of postoperative complications and functional impairment after multimodality treatment for limb and trunk wall soft-tissue sarcoma: Long term results from a monocentric series.
Stoeckle E; Michot A; Rigal L; Babre F; Sargos P; Henriques de Figueiredo B; Brouste V; Italiano A; Toulmonde M; Le Loarer F; Kind M
Eur J Surg Oncol; 2017 Jun; 43(6):1117-1125. PubMed ID: 28202211
[TBL] [Abstract][Full Text] [Related]
35. Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG "ANITA".
Schöffski P; Toulmonde M; Estival A; Marquina G; Dudzisz-Śledź M; Brahmi M; Steeghs N; Karavasilis V; de Haan J; Wozniak A; Cousin S; Domènech M; Bovée JVMG; Charon-Barra C; Marreaud S; Litière S; De Meulemeester L; Olungu C; Gelderblom H
Eur J Cancer; 2021 Jul; 152():26-40. PubMed ID: 34062484
[TBL] [Abstract][Full Text] [Related]
36. A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): a Children's Oncology Group prospective study.
Spunt SL; Million L; Chi YY; Anderson J; Tian J; Hibbitts E; Coffin C; McCarville MB; Randall RL; Parham DM; Black JO; Kao SC; Hayes-Jordan A; Wolden S; Laurie F; Speights R; Kawashima E; Skapek SX; Meyer W; Pappo AS; Hawkins DS
Lancet Oncol; 2020 Jan; 21(1):145-161. PubMed ID: 31786124
[TBL] [Abstract][Full Text] [Related]
37. Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma.
Worden FP; Taylor JM; Biermann JS; Sondak VK; Leu KM; Chugh R; McGinn CJ; Zalupski MM; Baker LH
J Clin Oncol; 2005 Jan; 23(1):105-12. PubMed ID: 15625365
[TBL] [Abstract][Full Text] [Related]
38. Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
D'Ambrosio L; Touati N; Blay JY; Grignani G; Flippot R; Czarnecka AM; Piperno-Neumann S; Martin-Broto J; Sanfilippo R; Katz D; Duffaud F; Vincenzi B; Stark DP; Mazzeo F; Tuchscherer A; Chevreau C; Sherriff J; Estival A; Litière S; Sents W; Ray-Coquard I; Tolomeo F; Le Cesne A; Rutkowski P; Stacchiotti S; Kasper B; Gelderblom H; Gronchi A;
Cancer; 2020 Jun; 126(11):2637-2647. PubMed ID: 32129883
[TBL] [Abstract][Full Text] [Related]
39. Outcomes of Elderly Patients with Advanced Soft Tissue Sarcoma Treated with First-Line Chemotherapy: A Pooled Analysis of 12 EORTC Soft Tissue and Bone Sarcoma Group Trials.
Younger E; Litière S; Le Cesne A; Mir O; Gelderblom H; Italiano A; Marreaud S; Jones RL; Gronchi A; van der Graaf WTA
Oncologist; 2018 Oct; 23(10):1250-1259. PubMed ID: 29650688
[TBL] [Abstract][Full Text] [Related]
40. Effect of anthracyclines/ifosfamide-based adjuvant chemotherapy for soft tissue sarcoma: a conventional and network Meta-analysis.
Hua Q; Xu G; Zhao L; Zhang T
J Chemother; 2021 Sep; 33(5):319-327. PubMed ID: 33501892
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
